DiabetesNCT07681024
Global Long-term Outcomes and Real-World Evaluation of Dexcom Continuous Glucose Monitoring System (Dexcom GLOW)
An observational study of Diabetes, run by DexCom, Inc..
Trial summary
Global Registry study Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Diabetes
- What is being tested?
- Dexcom CGM (Continuous Glucose Monitor)
- Type of treatment
- Medical device
- How many people
- 5,000 participants
- Where
- No sites listed yet
- Study dates
- 15 Jun 2026to 1 May 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The study intends to prioritize enrollment of participants living with Type 2 Diabetes (T2D): Intensive Insulin Therapy (IIT), Basal Insulin, and Non-Insulin Taking (NIT), participants.
Who may be able to join
- "1. Meets Dexcom CGM System Indications for Use (IFU) per approved commercial labeling
- 2. Has at least one HbA1C (Hemoglobin a1c) measurement obtained within the three (3) months prior to the start date of first Dexcom CGM System use in the study (blinded or unblinded, whichever first). For participants with prior CGM experience (CGM non-naive), this HbA1c measurement must also be at least three (3) months after the end of any CGM usewithin three (3) months prior to the Dexcom CGM System use start date that is at least three (3) months after any prior CGM use
- 3. Participant is willing and able to use Dexcom CGM System according to approved product labeling
- 4. Participant is willing and able to complete applicable patient reported outcome assessments/ surveys
- 5. Participant is willing and able to comply with the Clinical Investigation Plan
- 6. Participant is willing and able to comply with provider requirements for at least one or more provider encounters after CGM initiation according to applicable clinical practice guidelines
- 7. Participant or the participant's legally authorized representative must provide written informed consent prior to any study-related data collection or be enrolled under an IRB/EC/REB approved waiver of consent"
Who cannot join
- "1. Is contraindicated for a Dexcom CGM System per approved commercial labeling
- 2. In the Investigator's opinion, the participant is not considered to be a suitable candidate
- 3. Currently participating in another study and receiving and intervention study"
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Global Registry study
Read the detailed description
Global registry study to evaluate Dexcom CGM when used according to approved commercial labeling during standard clinical use across the globe.
- Conditions
- Diabetes
- Being tested
- Dexcom CGM (Continuous Glucose Monitor)
- Medical subject headings
- Diabetes Mellitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dexcom CGM (Continuous Glucose Monitor)Device
Also called Dexcom ONE, Dexcom Flex, Dexcom G7
Use Dexcom CGM according to approved commercial use. Evaluate HbA1c over time.
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluations
Evaluate outcomes of CGM use for each diabetes type within a given country
Measured: Up to 8 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jul 2026
- Study start15 Jun 2026 (estimated)
- Primary completion1 May 2030 (estimated)
- Study completion1 May 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 5,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- DexCom, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07681024
- Sponsor's protocol ID
- PTL-1000728
- Status last verified
- Jun 2026
- First submitted
- 26 Jun 2026
- Last updated
- 2 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Global Long-term Outcomes and Real-World Evaluation of Dexcom Continuous Glucose Monitoring System (Dexcom GLOW)
- ClinicalTrials.gov ID
- NCT07681024
- Acronym / sponsor ID
- PTL-1000728
- Conditions
- Diabetes
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 5,000 participants (estimated)
- Lead sponsor
- DexCom, Inc.Industry (pharma, biotech, devices)
- Study start
- 15 Jun 2026 (estimated)
- Primary completion
- 1 May 2030 (estimated)
- Study completion
- 1 May 2030 (estimated)
- First posted
- 2 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Global Registry study
Detailed description
Global registry study to evaluate Dexcom CGM when used according to approved commercial labeling during standard clinical use across the globe.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The study intends to prioritize enrollment of participants living with Type 2 Diabetes (T2D): Intensive Insulin Therapy (IIT), Basal Insulin, and Non-Insulin Taking (NIT), participants.
Key inclusion criteria (7 listed)
- "1. Meets Dexcom CGM System Indications for Use (IFU) per approved commercial labeling
- 2. Has at least one HbA1C (Hemoglobin a1c) measurement obtained within the three (3) months prior to the start date of first Dexcom CGM System use in the study (blinded or unblinded, whichever first). For participants with prior CGM experience (CGM non-naive), this HbA1c measurement must also be at least three (3) months after the end of any CGM usewithin three (3) months prior to the Dexcom CGM System use start date that is at least three (3) months after any prior CGM use
- 3. Participant is willing and able to use Dexcom CGM System according to approved product labeling
- 4. Participant is willing and able to complete applicable patient reported outcome assessments/ surveys
- 5. Participant is willing and able to comply with the Clinical Investigation Plan
Key exclusion criteria (3 listed)
- "1. Is contraindicated for a Dexcom CGM System per approved commercial labeling
- 2. In the Investigator's opinion, the participant is not considered to be a suitable candidate
- 3. Currently participating in another study and receiving and intervention study"
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dexcom CGM (Continuous Glucose Monitor)Also: Dexcom ONE, Dexcom Flex, Dexcom G7Use Dexcom CGM according to approved commercial use. Evaluate HbA1c over time. | Device | – |
Primary outcome
Evaluations
Time frame: Up to 8 years
Evaluate outcomes of CGM use for each diabetes type within a given country
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2026.
Related trials for Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabetes, run by DexCom, Inc..
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Margo Sedano (858-704-2428, margo.sedano@Dexcom.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluations (time frame: Up to 8 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2026.